PDS Biotechnology Leadership Change
PDS Biotechnology announced a significant board reconstitution with the immediate resignation of four directors (Kamil Ali-Jackson, Stephen Glover, Gregory Freitag, and Otis Brawley) and the appointment of three new directors: Deborah A. Ramsdell, John A. Dawson CBE, and Bruce Wendel. The new appointees bring extensive experience in drug development, commercialization, and regulatory affairs as the company prepares for Phase 3 trials of PDS0301.